This phase 2 clinical trial measures the 3-month response rate of selective internal radiotherapy combined with chemotherapy as well as toxic effects, overall and progression-free survival, and disease control rate for patients with unresectable intrahepatic cholangiocarcinoma.
This phase 2 clinical trial evaluates the use of hepatic arterial infusion of floxuridine plus systemic administration of gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma.
This cohort study examines data from the Swedish family-cancer data sets for family history, relative’s age at diagnosis, and other factors to identify the appropriate age for breast cancer screening.
This phase 2 clinical trial of patients with recurrence of breast cancer in the ipsilateral breast assesses the effectiveness of partial breast reirradiation after a second lumpectomy.
This cohort study develops a machine learning algorithm, using tumors from patients with advanced cancer, to aid in the prediction and classification of tumor types.
This multi-institutional phase 1 clinical trial assesses the safety and tolerability of adding a course of immunotherapy after completion of chemoradiotherapy in patients with node-positive cervical cancer.
This open-label, phase 1/2a study evaluates the safety and activity of fully human glucocorticoid-induced tumor necrosis factor (TNF) receptor–related protein agonist immunoglobulin G1 monoclonal antibody BMS-986156 with or without nivolumab in patients with advanced solid tumors.
This prespecified ancillary study of a randomized clinical trial compares the effects of daily marine ω-3 fatty acid supplementation vs placebo on risk of colorectal cancer precursors, including conventional adenomas and serrated polyps, in an average-risk US population.
This randomized clinical trial compared the effect of abemaciclib plus fulvestrant vs placebo plus fulvestrant on overall survival in women with hormone receptor–positive, ERBB2-negative advanced breast cancer that progressed during prior endocrine therapy.
This open-label, single-arm, pilot, phase 1b/2 clinical trial assesses outcomes following treatment with nab-paclitaxel plus gemcitabine plus the platinum-based cisplatin for patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
This cohort analysis examines the factors associated with successful immune suppression discontinuation in patients who undergo allogeneic hematopoietic cell transplantation and develops a model to estimate the probability of successful discontinuation.
This subgroup analysis of a randomized clinical trial compares trifluridine/tipiracil treatment with placebo for progression-free and overall survival among patients with previously treated metastatic gastric or gastroesophageal junction cancer who had or had not undergone gastrectomy.
This survey study assesses the role that physician cultural competency plays in racial disparities in cancer incidence and outcomes.
This cross-sectional study weighs the proportional associations of rising drug costs and use with increased Medicare Part D spending for a cohort of oral anticancer drugs used from 2013 through 2017.
This Special Communication reports on the discussions and decisions of a multidisciplinary group of experts and patient representatives convened by the US Food and Drug Administration and the National Cancer Institute to examine the state of the science of clinical trials of adjuvant therapies for renal cell carcinoma.
This systematic review evaluates quality indicators, their measurement properties, and their appropriateness for use in the care of patients with cancer who have advanced disease and/or are at the end of life.
This Viewpoint advocates for additional awareness and allocation of resources to address the increasing incidence of neuroendocrine tumors.
This Viewpoint explores how the association between increased vaccine hesitancy and measles outbreaks affect patients with cancer in the United States.
This Viewpoint describes progress toward applying insight into immune checkpoint inhibitor and angiogenesis inhibitor drugs toward cases of metastatic renal cell carcinoma.
In this essay, an oncologist’s describes how he uses the concept of positive deviance and Kaplan-Meier curves in face of treatment obstacles that seem insurmountable.
Create a personal account or sign in to: